Efficacy of a proprietary compound B in a humanized mouse model of psoriasis

Completed

• Conditions: flaking disease; psoriasis; 10003816; 10014982

• Registration Number: NL-OMON34173
• Lead Sponsor: TNO

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 26

Inclusion Criteria

Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use localcorticosteriods or ointments to prevent dry skin (see appendix 2).

Exclusion Criteria

Psoriasis patients: These patients have not received light therapy or another form of systemic treatment (methotrexaat, cyclosporin A,anti-TNF treatments). Gender or age of the adults are not a exclusion criteria.(see appendix 2)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Effect on the psoriatic process is tested by histology and immuno-histochemical<br /><br>techniques in the transplanted biopsies.<br /><br>Main read-out epidermal thickness.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Serum markers in blood of transplanted mice will be studied together with<br /><br>markers on culture cells from psoriasis patients.</p><br>